Segment and Geographic Information - Reconciliation of Reportable Segment Operating Income (Loss) to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Total revenue	$ 154,317	$ 178,366
Amortization of other intangible assets	12,500	11,500
Purchase accounting impact on inventory		2,869
Restructuring charges	1,120	1,461
Merger and acquisition costs and costs related to share repurchase	4,321	11,838
Total operating loss	(26,677)	(27,685)
Interest income, net	10,081	10,665
Other, net	682	1,145
Loss before income taxes	(15,914)	(15,875)
Completed Technology
Segment Reporting Information [Line Items]
Amortization of other intangible assets	5,627	4,168
Intangible Assets Excluding Completed Technology
Segment Reporting Information [Line Items]
Amortization of other intangible assets	6,862	7,372
Sample Management Solutions
Segment Reporting Information [Line Items]
Total revenue	79,005	75,455
Multiomics
Segment Reporting Information [Line Items]
Total revenue	62,720	61,089
B Medical Systems
Segment Reporting Information [Line Items]
Total revenue	12,592	41,822
Operating Segments
Segment Reporting Information [Line Items]
Total operating loss	(8,716)	40
Operating Segments | Revision of Prior Period, Adjustment
Segment Reporting Information [Line Items]
Total operating loss		8,500
Operating Segments | Sample Management Solutions
Segment Reporting Information [Line Items]
Total operating loss	(856)	(2,998)
Operating Segments | Multiomics
Segment Reporting Information [Line Items]
Total operating loss	(3,451)	(3,265)
Operating Segments | B Medical Systems
Segment Reporting Information [Line Items]
Total operating loss	(4,409)	6,303
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Other unallocated corporate expense	$ 31	$ 17